Rapid Chlamydia and Gonorrhea Testing for Urgent Care Centers
Urgent care is where millions of patients seek STI testing every year, often their only touchpoint with the healthcare system. Most CT/NG results still take days to return from a central lab. By then, patients are gone.
Same-Visit STI Testing. No Lab Send-Out Required.
The binx io is an FDA-cleared, CLIA-waived, molecular point-of-care platform for chlamydia (CT) and gonorrhea (NG), delivering PCR-accurate results in approximately 30 minutes with no laboratory or lab-trained staff required.1,2,3
Lab Turnaround Times Are Costing You Patients
Send-out testing creates a multi-day window between testing and treatment, during which a significant share of patients never return. POC testing collapses that window to a single visit, directly improving treatment rates and reducing onward transmission.
- 2-3 days of processing time⁶ Patient likely gone before results return
- ~20% lost to follow-up⁴ Patients who never return for treatment or results
- Empiric antibiotic use Treatment decisions often made without confirmed diagnosis, undermining stewardship⁵
- Onward transmission risk Untreated patients continue spreading infection in the community
- ~30 minutes to result Same visit, same provider, same day
- In-visit test results Reducing patients who never return for treatment
- Targeted, confirmed treatment Diagnosis-driven prescribing supports antibiotic stewardship⁵
- Reduced transmission Patients treated in-visit leave with a confirmed result and prescription
Lab-Equivalent Accuracy in a Non-Lab Setting
| Chlamydia Sensitivity / Specificity | Gonorrhea Sensitivity / Specificity | |
|---|---|---|
| Female | 96.1% / 99.1% | 100.0% / 99.9% |
| Male | 92.5% / 99.3% | 97.3% / 100.0% |
It Fits Your Workflow
No lab staff, no certification, no complex setup. Fully automated with clear detected/not detected results, LIS/EMR integration, and an established reimbursement path for CT/NG point-of-care testing.
CLIA- Waived
No laboratory certification required. Any trained staff member can operate the instrument in a point-of-care setting.
Connectable
Ability to route directly into your existing systems. No manual transcription, no extra steps, no lag between result and clinical action.
Established reimbursement
CPT codes for CT/NG point-of-care testing are recognized by Medicare, Medicaid, and most commercial payers.Sources
1. Van Der Pol B, et al. Clinical Performance of the BD ProbeTec™ CT/GC Assay... [2,445-person multicenter study]. JAMA Network Open, 2020. https://doi.org/10.1001/jamanetworkopen.2020.4819 2. binx health io® CT/NG Assay Instructions for Use, MOB-ART-0700 v4.0, May 2022. 3. FDA 510(k) Summary, K191352. https://www.accessdata.fda.gov/cdrh_docs/pdf19/K191352.pdf 4. Schwebke JR, Sadler R, Sutton JM, Hook EW 3rd. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. Sex Transm Dis 1997;24:181-184. https://pubmed.ncbi.nlm.nih.gov/9101628/ 5. Huntington S, Weston G, Adams E. Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health services. Ther Adv Infect Dis, 2021. https://doi.org/10.1177/20499361211061645 6. Labcorp. Chlamydia/Gonococcus, NAA (Test 183194) — Result Turnaround Time. https://www.labcorp.com/tests/183194/chlamydia-gonococcus-naa
